|
Baseline
|
|
Median (IQR), age (years)a
|
33 (29–39)
|
33.5 (29–40)
|
35 (28–42)
|
36 (30–43)
|
0.278
|
|
Female, %(n)b
|
36.9 (55)
|
49.6 (263)
|
83.1 (147)
|
90.1 (82)
|
< 0.001
|
|
WHO stage 1–3,% (n)c
|
69.8 (104)
|
84.9 (450)
|
84.8 (150)
|
93.4 (85)
|
< 0.001
|
|
WHO stage 4, % (n)c
|
30.2 (45)
|
15.1 (80)
|
15.3 (27)
|
6.6 (6)
| |
|
CD4+, Median (IQR)d (cells /mm3)
|
96 (35–187)
|
132 (66–196)
|
150 (75–224)
|
140 (81–214)
|
0.002
|
|
Mean (SD) viral load (log copies/ml)e
|
5.2 (0.9)
|
5.0 (0.8)
|
4.7 (0.9)
|
4.5 (1.0)
|
< 0.001
|
|
Tuberculosis at baseline
|
55.7 (83)
|
43.2 (229)
|
32.8 (58)
|
20.7 (19)
|
< 0.001
|
|
Follow-up
|
|
CD4+ increase > 50: baseline to 6 months, %(n) (N = 741)
|
78.3 (83)
|
80.4 (328)
|
74.0 (111)
|
70.1 (54)
|
0.141
|
|
CD4+ increase > 50: baseline to 12 months, %(n) (N = 512)
|
85.0 (68)
|
85.7 (252)
|
83.2 (79)
|
83.7 (36)
|
0.935
|
|
CD4+ increase > 50: baseline to 18 months, %(n) (N = 237)
|
85.7 (24)
|
91.4 (127)
|
91.7 (44)
|
86.4 (19)
|
0.631
|
|
Undetectable viral load at 6 months, % (n) (N = 810)
|
90.7 (107)
|
93.7 (419)
|
93.8 (152)
|
92.7 (77)
|
0.679
|
|
Undetectable viral load at 12 months, % (n) (N = 524)
|
91.5 (75)
|
95.0 (283)
|
96.0 (96)
|
90.9 (40)
|
0.401
|
|
Undetectable viral load at 18 months, % (n) (N = 242)
|
82.1 (23)
|
93.0 (132)
|
93.9 (46)
|
87.0 (20)
|
0.195
|
